Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report released on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group raised shares of Galmed Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, July 24th. View […]

Leave a Reply

Your email address will not be published.

Previous post Russian alternative overtakes historic Coca-Cola sales
Next post Barclays Lowers Darden Restaurants (NYSE:DRI) Price Target to $165.00